Precision BioSciences, Inc.
HealthcareNASDAQ:DTIL · NASDAQ Global Select
-$0.07 today
Vol 0.24M · Avg 0.32M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-50.5%
avg -75.5%
ROIC
-35.5%
avg -37.2%
ROA
-30.2%
avg -30.7%
Analysis
ROA is currently the strongest return metric at -30.2% versus its period average of -30.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael Amoroso | President, Chief Executive Officer & Director | $1.16M | — | 48 | $243,392.00 | 1.90% |
John Alexander Kelly | Chief Financial Officer & Principal Accounting Officer | $717,056.00 | — | 59 | $125,883.00 | 0.98% |
Dario Scimeca | General Counsel & Secretary | $659,641.00 | — | 51 | $56,457.00 | 0.44% |
Jefferson J. Smith | Co-Founder & Chief Research Officer | $640,195.00 | — | 53 | $121,926.00 | 0.95% |
Cassie Gorsuch | Chief Scientific Officer | — | — | — | — | — |
Naresh Tanna | Chief of Staff to Chief Executive Officer & Head of Investor Relations | — | — | — | — | — |
Neil Leatherbury | Senior Vice President and Head of Chemistry, Manufacturing & Controls | — | — | — | — | — |
Cindy Atwell | Chief Development & Business Officer | — | — | — | — | — |
Juli Blanche | Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$82,058.21
Sells
12
$529,330.31
Net Sentiment
$447,272.10
Net selling
Most Active
Kelly John Alexander
4 transactions
1–10 of 19
Analysis
Insiders reported 7 buys worth $82,058.21 and 12 sells worth $529,330.31 over the last 12 months. That adds up to net selling of $447,272.10. Kelly John Alexander was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +55.3% | +17.4% (10yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +55.3% over three years. Forward estimates point to Revenue at +17.4% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.70M
ALX Oncology Holdings Inc.
NASDAQ:ALXO
$212.61M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$211.08M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
Repare Therapeutics Inc.
RPTX
$114.24M
Adverum Biotechnologies, Inc.
ADVM
$96.26M
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
$61.36M
Metagenomi, Inc. Common Stock
MGX
$45.18M
aTyr Pharma, Inc.
ATYR
$43.18M
Quince Therapeutics, Inc.
QNCX
$5.20M
Who manages DTIL?
Precision BioSciences, Inc. (DTIL) lists 9 active executives. The top listed executive is Cassie Gorsuch, Chief Scientific Officer.
Are DTIL insiders buying or selling?
Recent insider activity shows net selling of $480,470.05.
Explore More
Continue the stock analysis
Jump to another research area for this company.